Background and aims
===================

Science alone could never answer the great questions of humanity, nor could technology lead to improvement on its own. But when the two meet, progress can take place, and such is the case of discovering the molecular profile of phenotypic manifestations of various illnesses, which can eventually lead to the discovery of suitable and effective targeted therapies. Nowadays, molecular diagnosis for cancer patients prior to establishing the course of treatment is becoming a common presence in clinical practice, since nucleic acid sequencing has developed into a useful tool in the hands of medical researchers.

During the past years, the attention of healthcare practitioners and clinical researchers has begun to shift from treating patients already affected by various diseases to what is known as "predictive, preventive, and personalized medicine" (PPPM), and nowhere is this trend better illustrated than in the field of oncology \[[@b1-cm-88-278]\]. For a while now, cancer has not been thought of as a disease, but a multifaceted, heterogeneous complex of genotypic and phenotypic manifestations that lead to tumorigenesis. Among tumors, breast cancer is the most frequent type of cancer diagnosed in women across the world, with an incidence of 22.9% according to GLOBOCAN-2008 \[[@b2-cm-88-278]\], and the second most common type of cancer for both sexes combined, after lung cancer; at the same time, it is the principal cause of cancer death in women \[[@b2-cm-88-278]\].

In the pursuit for the best response to therapy for each patient, caregivers are beginning to rely on more than the histopathological grading and staging of the disease and the general health of the patient. Due to recent advances in molecular and genetic research, clinicians now consider more specific information when deciding on therapeutic approaches: gene and molecular expression of tumors, mutation status of genes involved in a particular disease, polymorphisms or copy number variations. As an example, it is worth mentioning the increased capabilities of oncologists to predict the response to the recombinant monoclonal antibody trastuzumab (Herceptin) in HER2 positive breast cancer patients \[[@b3-cm-88-278]\], or the response to cetuximab and panitumumab in mutated BRAF and/or KRAS colorectal adenocarcinoma patients \[[@b4-cm-88-278]\]. The ability to foresee if a patient will respond to a therapeutic scheme based on their molecular profile does not only translate into potentially improving their outcome, but it also means an important step towards achieving the goal of personalized medicine.

As Bateman and Quackenbush stated in a 2009 editorial from the Bioinformatics Journal \[[@b5-cm-88-278]\], the most outstanding outcome of sequencing and publishing the first reference human genome was not only knowing the genome itself, but all the technological advances that contributed to it, and the accelerated scientific progress derived from the Human Genome Project (HGP) \[[@b6-cm-88-278]\]. Among the recent scientific and technical advances that impact medical research is next generation sequencing, which has the potential to improve clinicians' approach on diagnosis and targeted therapies \[[@b7-cm-88-278],[@b8-cm-88-278]\].

Leading suppliers of biomedical equipment have used these recent technological discoveries to produce various sequencing platforms based on the most recent advances in the field of next generation sequencing. Or, to be more precise, in the field of second generation sequencing, to better differentiate between Sanger sequencers and the more recent SMRT sequencing techniques (Single Molecule Real Time) developed by Pacific Biosciences \[[@b9-cm-88-278]\], which are not the object of this paper. Many second generation sequencing platforms are available on the market, displaying a wide range of performances, reading capabilities, prices and possible applications, as seen in [Table I](#tI-cm-88-278){ref-type="table"} \[[@b8-cm-88-278],[@b10-cm-88-278]--[@b16-cm-88-278]\] but they all need certain crucial steps which are summarized in [Figure 1](#f1-cm-88-278){ref-type="fig"}. These machines, which are becoming a familiar presence in molecular biology and clinical research laboratories, are produced and developed by the key players in the field, Roche (454 GS FLX, GS Junior), Illumina/Solexa (GAII, MiSeq, HiSeq) and Life Technologies (SOLiD, Ion Torrent, Ion Proton). The purpose of this paper is to provide a brief overview of some of the applications for breast cancer research developed for these platforms, as well as an outline of the sequencing workflow, focusing on the benchtop instruments which are more likely to be found in clinical research laboratories (GS Junior from Roche, MiSeq from Illumina, Ion Torrent from Life Technologies).

Methods
=======

454/Roche technology and workflow
---------------------------------

454 Life Sciences, a biotechnology company from Connecticut, launched the first massively parallel DNA sequencer, the 454, probably the most widely used platform today \[[@b13-cm-88-278],[@b15-cm-88-278]\]. After the first 454 machine became available on the market, it underwent several improvements regarding its performance and output, leading up to the benchtop version, the GS Junior. The technology employed by all 454 systems is sequencing by synthesis, and the actual sequencing is performed by pyrosequencing, in which a complex of enzymes and optical devices discriminate each pyrophosphate that is released during the attachment of nucleotides by the polymerase, but only if there are no extended homopolymer repeats \[[@b17-cm-88-278]--[@b19-cm-88-278]\]. The workflow is comparable to the one used when sequencing on the Ion Torrent. The input samples can be genomic DNA from BACs, plastids, bacteria, plants or animals for *de novo* sequencing, amplicons generated for targeted sequencing or re-sequencing, or cDNA.

The samples are first quantified and the DNA is randomly fragmented usually by nebulisation. After performing some end-repair procedures, adaptors are ligated to the double stranded DNA fragments. Two types of adaptors are used, A and B, the latter carrying a biotin group which contributes to the final separation of fragments that can be used for pyrosequencing. After ligation and denaturation, the mixture of fragments is exposed to streptavidin beads for library purification. Since the homozygous A-A fragments do not contain any biotin marker, they are flushed away. The homozygous B-B fragments are also eliminated, being constrained by the double biotin-streptavidin bond. What remains are the heterozygous fragments that constitute the DNA library which, prior to sequencing, needs to undergo an amplification step via emulsion PCR (emPCR) \[[@b7-cm-88-278]\]. This is performed by using DNA capture beads on which each fragment is attached via the A adaptor at a one-to-one ratio by using precise and limiting dilutions. The water-in-oil emulsion is designed to trap each bead with a single DNA fragment attached, creating a high number of micro-reactors equipped with all the necessary PCR ingredients, where massive parallel amplification takes place. In this manner, hundreds of thousands of clonally amplified DNA fragments are generated on the surface of each capture bead \[[@b20-cm-88-278]\]. After the water-in-oil emulsion is broken, the amplified library is placed on a fiber optic "MicroTiterPlate" containing millions of wells sized in such a way that each well is occupied by only one capture bead \[[@b21-cm-88-278]\]. Enzyme beads are also added to each well, containing DNA polymerase, luciferase and ATP sulfurylase, necessary for recording each pyrophosphate released upon nucleotide incorporation.

During the following step, the sequencing *per se*, the plate is flushed with separate solutions containing each of the four nucleotides (dATP, dTTP, dGTP, dCTP) in a sequential manner and a precise, pre-defined order. As each nucleotide is incorporated into the chain based on complementarity, the pyrophosphate that is displaced during phosphodiester bond formation is converted by sulfurylase into ATP. During a subsequent reaction, luciferase oxidizes luciferin in the presence of ATP and oxygen, leading to the formation of a series of compounds and a quantum of light which is recorded by the CCD camera of the sequencer. If the template strand contains a homopolymer stretch, the intensity of the emitted light is directly proportional to the number of identical bases which were added to the new, complementary strand, but this may be a source of errors, since the light signal that is recorded is not always conclusive for the exact number of incorporated bases \[[@b22-cm-88-278]\]. Other errors are prevented by flushing the PicoTiter plate with the enzyme apyrase between each run of nucleotides added to the reaction.

The raw data is processed and recorded in the form of a flowgram, and then the primary reads are assembled by overlapping multiple reads into longer strands to obtain consensus reads. The sequences are further mapped and compared against the known information from various databases.

Illumina/Solexa technology and workflow
---------------------------------------

Illumina uses a different approach for sequencing, the dye terminator technique, a method originally developed by the researchers from Manteia Predictive Medicine and from Solexa, a company bought by Illumina in 2007. Another particularity consists in the fact that the sequencing uses DNA libraries amplified through bridge-PCR. For this, the genomic DNA is randomly fragmented by sonication, the ends are repaired, and poly-A overhangs are added to the 3′ ends of each fragment by Klenow DNA polymerase exo(−) \[[@b9-cm-88-278]\]. The poly-adenylated tails are used to add partially complementary specific adaptors to both ends of the double stranded fragments. The library is then size selected and placed on the flow cell for bridge-PCR amplification \[[@b7-cm-88-278],[@b15-cm-88-278]\]. The flow cell used by Illumina is a solid support with the inner surface functionalized with two distinct oligonucleotide primers, forward and reverse, which are complementary to the two adaptors ligated on the DNA library \[[@b18-cm-88-278]\]. The primers are attached with their 5′ end to the surface of the flow cell by a flexible linker, so that molecules that are amplified from a particular DNA fragment from the original library remain clustered together in groups of about 1,000 clonal amplicons. Prior to the actual sequencing, the amplicons are linearized and sequencing primers are hybridized to the 3′ ends. Then, a series of reagents is added to the flow cell for the "sequencing by synthesis" step.

Each round of interrogation is based on the elongation of the newly synthesized strand with only one nucleotide. The nucleotides used by Illumina platforms are modified in two ways. First, each of the four bases (A, T, C, G) is attached to a specific fluorochrome, so they do not need to be flushed over the flow cell separately \[[@b23-cm-88-278]\]. The second modification consists in the fact that the bases resemble the dideoxynucleotides used in Sanger sequencing, but they are "reversible terminators", since the 3′-OH is blocked by a cleavable fraction that prevents the incorporation of more than one base to the sequencing strand \[[@b8-cm-88-278]\]. Therefore, each query is recorded independently, and the sequencing cannot continue until the terminator tag is released from the nucleotide to expose the hydroxyl group. This method overcomes the limitation of the 454 platforms regarding the biased output when incorporating homopolymer repeats. It also offers real-time feedback after each synthesis cycle, and provides faster results \[[@b17-cm-88-278]\]. Nonetheless, sequencing with Illumina platforms is prone to some weaknesses, mainly concerning read length, and the reasons may be connected to incomplete and uneven removal of the terminating group. Still, the accuracy of reads makes Illumina the platform of choice in many laboratories, especially after the release of its bench top model, MiSeq, suitable for small genomes, exomes or targeted sequencing \[[@b11-cm-88-278]\].

Ion Torrent technology and workflow
-----------------------------------

Ion Torrent, the "Personal Genome Machine" (PGM^TM^) released by Life Technologies in 2011, brings a new approach to second generation sequencing. Although the technology is still based on sequencing by synthesis, it does not require fluorescently labeled or chemiluminescent dNTPs, or an image-based detection of incorporated nucleotides. Instead, it uses a disposable chip built on the semiconductor technology to detect not the pyrophosphate released during nucleotide incorporation, but the proton that is also discharged during this process. In other words, the Ion Torrent chip acts as a pH-meter, detecting subtle pH shifts which occur when a phosphodiester bond is formed during elongation of the sequencing strand \[[@b23-cm-88-278]\]. This novel technology, which does not require any optical devices and allows faster runs, together with its low price and automated possibilities for library preparation, make the Ion Torrent a suitable instrument for targeted sequencing or small genome analyses.

The workflow starts with the construction of DNA libraries. Genomic or cDNA is first fragmented into 200--400 bp strands, the ends are repaired, and the library is amplified and purified; then specific adaptors are attached to the ends of the fragments, and the gaps are filled in. When performing multiplex sequencing, such as sequencing DNA for more than one patient, specific barcodes are added to the fragments. The library is then size-selected and quality-controlled, either by using an Agilent Bioanalyzer or traditional quantitative PCR (qPCR). Next step is amplification via emulsion PCR \[[@b7-cm-88-278]\]. After amplification, which resembles what we previously described for the 454 platform, the amplicon library undergoes template bead enrichment. For the PCR amplification and library enrichment, Ion Torrent developed the "Ion OneTouch" system, which automates the process and reduces hands-on time a great deal \[[@b12-cm-88-278]\]. After this step, the DNA library is loaded on the chip and centrifuged, to ensure that each well of the chip is occupied by a template bead, and the sequencing process is initiated \[[@b15-cm-88-278]\].

As previously mentioned, Ion Torrent technology is based on sequencing by synthesis, which consists in flooding the chip with individual, native nucleotides in a defined order. When complementary nucleotides are added to the sequencing strand by the DNA polymerase, the proton that is released causes a pH modification that is measured by sensors located at the bottom of each well. Since there are no optical devices involved, the sequencing reactions can proceed at a reasonably high rate \[[@b10-cm-88-278],[@b24-cm-88-278]\]. Still, aside from the improvements brought by the Ion Torrent PGM^TM^, the problem of the homopolymer repeats still remains unsolved for the pyrosequencing based platforms, regardless of the way they detect nucleotide incorporation -- as fluorescent signal or as a pH shift \[[@b14-cm-88-278],[@b25-cm-88-278]\]. However, the release of the new Ion Proton and the rapid advancements in this field might lead to a solution to this limitation.

Results and discussion
======================

NGS applications in breast cancer research
------------------------------------------

Second generation sequencing covers a wide range of applications, from whole genome sequencing (WGS) for individual patients or for other groups of organisms to exome sequencing, targeted re-sequencing and functional studies focused on the DNA -- protein interactions (chromatin immunoprecipitation ChIP), which all have the potential to bring improvement in the quest for personalized medicine \[[@b26-cm-88-278]\]. Human genetic variation applications developed for NGS include the evaluation of Single Nucleotide Polymorphisms (SNPs), Structural Variations (SVs) and Indels. The knowledge derived from these investigations can provide grounds for assessing possible links between genetic variations and different diseases, with high applicability in the field of oncology. Among these studies, the most common are genome-wide association studies (GWAS) and functional characterization of SNPs \[[@b16-cm-88-278],[@b27-cm-88-278]\]. Many of these single nucleotide polymorphisms are connected to various pathological conditions either by abnormal gene expression or by altered protein structure and/or function, so they hold the potential to be used as genetic markers in the clinic to predict the risk of developing a certain disease, prognostic or response to therapy \[[@b28-cm-88-278],[@b29-cm-88-278]\].

Breast cancer epidemic has reached alarming levels, so considerable efforts are made to learn more about this disease and the genetic alterations that lead to tumorigenesis, including cell growth, migration, angiogenesis and metastasis. Another aspect which requires attention is the lack of consistent and predictable response to main-stream chemotherapy used for mammary tumors classified according to traditional histopathological or other commonly used grading systems (TNM, Nottingham, etc). The reason for this is breast cancer heterogeneity -- both inter-tumor and intra-tumor, which causes tumor-cell populations to behave differently and unpredictably \[[@b30-cm-88-278]--[@b32-cm-88-278]\].

The extensive knowledge unraveled at the end of the Human Genome Project enabled biochemical companies to produce commercial kits designed for the study of breast cancer, and cancer in general, with the help of NGS. Today, the market offers a wide range of cancer panels which can be used to discover the degree of tumor-specific genomic alterations by targeted re-sequencing of cancer genomes \[[@b13-cm-88-278]\]. Some of the kits are produced by the manufacturers of next generation sequencers, to be used on their own machines -- such as the IonAmpliseq Cancer Panel from Life Technologies, and the TruSeq Cancer Panel from Illumina, while others are generic and can be performed on many instruments. The cancer panels differ also with regard to the number of genes they contain and to the specificity of the results they produce. For instance, BRCA MASTR™ Dx from Multiplicom was designed in order to identify mutations in two tumor suppressor genes responsible for inherited breast and ovarian cancer, namely BRCA1 and BRCA2. On the other hand, the IonAmpliseq Comprehensive Cancer panel from Life Technologies can pinpoint mutations in 409 genes that are linked to the process of tumor formation and progression. Some information regarding the most frequently used commercial kits for NGS based studies in cancer research is presented in [Table II](#tII-cm-88-278){ref-type="table"} \[[@b33-cm-88-278]--[@b39-cm-88-278]\].

Five to ten percent of all mammary tumors are hereditary, and are connected to germline mutations in the genes BRCA1 and BRCA2 \[[@b40-cm-88-278],[@b41-cm-88-278]\]. Still, only about 25% of familial breast cancers are associated with mutations in the two tumor suppressor genes \[[@b35-cm-88-278],[@b42-cm-88-278]\]. Although scientists are far from pinpointing all genomic alterations that lead to this multifactorial, heterogeneous disease, some mutated genes were observed to take an active part in tumorigenesis, such as tumor suppressors (APC, CHEK 2, TP53, PTEN), DNA repair genes (NBN, MUTYH, MLH1, BRIP1), members of important signaling pathways implicated in cell division, proliferation and survival (ABL1, ATM, BRAF, FGFR1, JAK2, KRAS) or genes that encode for cell adhesion molecules (CDH1, CTNNB1, EPCAM) (See [Supplementary Table I](#s1-cm-88-278){ref-type="supplementary-material"}) \[[@b43-cm-88-278]\]. These genes and others can be targeted and analyzed with the commercial cancer panels designed for next generation sequencing.

Conclusions
===========

For the time being, the main purpose of these targeted re-sequencing studies is to assess risk or prognosis, but, with NGS platforms and reagents becoming more affordable and approaching the \$1,000/genome threshold, sequencing can achieve more clinical applications \[[@b20-cm-88-278]\]. Automation made benchtop NGS machines affordable also from the time perspective, since the results for targeted sequencing can be obtained within a work day, so they have the potential of becoming familiar presences in clinics. Thus, geneticists can provide caregivers rapid and essential information on the molecular profile of tumors, which can help in diagnosis, assessment of disease, and in planning the most appropriate treatment scheme, with maximum efficiency and minimal side effects \[[@b24-cm-88-278],[@b28-cm-88-278]\]. Once this is accomplished, medicine will be one step closer to achieving its ultimate goal, personalized therapy. And when this aim is reached, chances are that next generation sequencing will have played a crucial role in this endeavor.

Supplementary materials
=======================

###### 

Some of the genes involved in tumorigenesis, which are targeted in commercially available sequencing kits.

  Gene     Location    Full name                                                                 UniGene     Function                                                                                                                   
  -------- ----------- ------------------------------------------------------------------------- ----------- -------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------
  ABL1     9q34.1      c-abl oncogene 1, non-receptor tyrosine kinase                            Hs.431048   Cell growth, survival, adhesion, differentiation, DNA damage response, apoptosis                                           Chronic myeloid leukemia (CML), when translocated with BCR - also found in AML and ALL
  APC      5q21-q22    adenomatous polyposis coli                                                Hs.158932   Tumor suppressor, controls cell division                                                                                   Colorectal cancer, Familial adenomatous polyposis
  ATM      11q22.3     ataxia telangiectasia mutated                                             Hs.367437   Cell division, DNA repair, normal development of nervous and immune system                                                 When homozygous, ataxia-telangiectasia. When heterozygous, breast cancer and others
  BARD1    2q34-q35    BRCA1 associated RING domain 1                                            Hs.591642   Cell growth and division, together with BRCA1                                                                              Uncertain risk in breast cancer and neuroblastoma
  BRAF     7q34        v-raf murine sarcoma viral oncogene homolog B1                            Hs.550061   In RAS/MAPK pathway, role in differentiation, migration, apoptosis                                                         Cardiofaciocutaneous and multiple lentigines syndromes. Oncogene, somatic mutations associated with many cancers
  BRCA1    17q21       breast cancer 1, early onset                                              Hs.194143   Tumor suppressor, gene regulation                                                                                          Breast cancer, ovarian cancer, pancreatic cancer
  BRCA2    13q12.3     breast cancer 2, early onset                                              Hs.34012    Tumor suppressor, gene regulation                                                                                          Breast cancer, ovarian, pancreatic, prostate. Also Fanconi anemia type D1 when homozygous
  BRIP1    17q22.2     BRCA1 interacting protein C-terminal helicase 1                           Hs.128903   DNA damage repair                                                                                                          Breast cancer when inherited heterozygous. Fanconi anemia when homozygous
  CDH1     16q22.1     cadherin 1, type 1, E-cadherin (epithelial)                               Hs.461086   Cell adhesion, cell signaling                                                                                              Breast cancer, hereditary diffuse gastric cancer
  CHEK2    22q12.1     checkpoint kinase 2                                                       Hs.291363   Tumor suppressor, detection of DNA damage and strand breaks                                                                Breast cancer, Li-Fraumeni syndrome, other cancers
  CTNNB1   3p21        catenin (cadherin-associated protein), beta 1                             Hs.476018   Cell adhesion, cell signaling                                                                                              Pilomatricoma; colorectal, liver, ovarian cancer, medulloblastoma; desmoid fibromatosis
  EPCAM    2p21        epithelial cell adhesion molecule                                         Hs.542050   Calcium independent cell adhesion molecule in normal epithelium and gastrointestinal carcinoma                             Hereditary nonpolyposis colorectal cancer, congenital tufting enteropathy
  ERBB2    17q12       Her-2/neu, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2      Hs.446352   Encodes for growth factor receptors                                                                                        Amplification found breast cancer, overexpression in receptors leads to aggressive forms of cancer
  FGFR1    8p12        fibroblast growth factor receptor 1                                       Hs.264887   Cell division, regulation of cell growth and maturation                                                                    Alterations found in cancers via proliferation, migration, angiogenesis
  HRAS     11p15.5     v-Ha-ras Harvey rat sarcoma viral oncogene homolog                        Hs.37003    Regulates cell division through signal transduction                                                                        Oncogenes; involved in bladder, thyroid, kidney cancer; Costello syndrome
  JAK2     9p24        Janus kinase 2                                                            Hs.656213   Cell growth and proliferation, role in hematopoiesis                                                                       Leukemia, essential thrombocythemia, primary myelofibrosis
  KRAS     12p12.1     v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog                      Hs.505033   GTPase involved in cell division and differentiation                                                                       Oncogenes; involved in pancreatic, lung, and colorectal cancers; cardiofaciocutaneous and Noonan syndromes
  MLH1     3p21.3      mutL homolog 1, colon cancer, nonpolyposis type 2                         Hs.195364   DNA damage repair                                                                                                          Lynch syndrome; when homozygous, also causes leukemia and neurofibromatosis
  MRE11A   11q21       MRE11 meiotic recombination 11 homolog A                                  Hs.192649   DNA double-strand break repair, telomere length maintenance, homologous recombination via exo- and endonuclease activity   Ataxia telangiectasia-like disorder, blocks meiotic recombination
  MSH2     2p21        mutS homolog 2, colon cancer, nonpolyposis type 1                         Hs.597656   DNA damage repair                                                                                                          Lynch syndrome; endometrium, stomach, intenstine, liver cancer, etc. Homozygous mutations can also cause leukemia or lymphoma
  MSH3     5q11-q12    mutS homolog 3                                                            Hs.280987   Heterodimer with MSH2, involved in post-replicative DNA mismatch repair system                                             Endometrial cancer
  MSH6     2p16        mutS homolog 6                                                            Hs.445052   Post-replicative DNA damage repair                                                                                         Lynch syndrome; endometrium, stomach, intenstine, liver cancer, etc. Homozygous mutations can also cause leukemia or lymphoma
  MUTYH    1p34.1      mutY homolog                                                              Hs.271353   DNA damage repair by MYH glycosylase                                                                                       Familial adenomatous polyposis
  NRAS     1p13.2      neuroblastoma RAS viral (v-ras) oncogene homolog                          Hs.486502   Cell division and differentiation                                                                                          Noonan syndrome, melanoma, other types
  NBN      8q21        nibrin                                                                    Hs.492208   DNA damage repair                                                                                                          Breast, ovarian, prostate cancer, melanoma, leukemia, Nijmegen breakage syndrome
  PALB2    16p12.2     partner and localizer of BRCA2                                            Hs.444664   Interacts with BRCA2; tumor suppressor                                                                                     Breast cancer when inherited heterozygous. Fanconi anemia when homozygous
  PIK3CA   3q26.3      phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha   Hs.553498   Role in signaling cascades involved in cell growth, survival, proliferation, motility and morphology                       Oncogene, in breast, colorectal, ovarian, liver, gastric, lung cancers
  PTEN     10q23.3     phosphatase and tensin homolog                                            Hs.500466   Tumor suppressor, involved in apoptosis                                                                                    Somatic mutations in prostate and endometrial cancer, glioblastoma, astrocytoma, melanoma
  RAD50    5q31        RAD50 homolog                                                             Hs.633509   DNA damage repair by holding the broken ends together during process                                                       Suggested to contribute to breast cancer
  RAD51C   17q25.1     RAD51 homolog C                                                           Hs.412587   DNA damage repair and meiotic homologous recombination                                                                     Hereditary breast and ovarian cancer, Fanconi anemia
  SMAD4    18q21.1     SMAD family member 4                                                      Hs.75862    Controls gene activity and regulates cell proliferation                                                                    Colon, pancreas cancer; hereditary hemorrhagic telangiectasia, juvenile polyposis syndrome
  SRC      20q12-q13   v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog                 Hs.195659   Proto-oncogene with role in regulation of embryonic development and cell growth                                            Increased activity in colon carcinoma cells
  STK11    19p13.3     serine/threonine kinase 11                                                Hs.515005   Tumor suppressor, role in tissue polarization and apoptosis                                                                Breast cancer, non-small cell lung carcinoma, melanoma, pancreatic cancer; Peutz-Jeghers syndrome
  TP53     17p13.1     tumor protein p53                                                         Hs.437460   Tumor suppressor, "guardian of the genome" (Lane, 1992)                                                                    Breast, bladder, colorectal cancer, osteosarcoma, Li-Fraumeni syndrome
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###### 

Brief characterization of some Second Generation Sequencing platforms.

  Producer              Roche                                                   Illumina/Solexa                                                       Life Technologies                                                                                                                                                                                                                                                            
  --------------------- ------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------ -------------------------- --------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------
  **Seq method**        SBS Pyro                                                SBS Pyro                                                              SBS RDT                                           SBS RDT                                                      SBS RDT                    SBS                                                       SBS H^+^                                                                 SBS H^+^
  **Amplification**     emPCR                                                   emPCR                                                                 Bridge PCR                                        Bridge PCR                                                   Bridge PCR                 emPCR                                                     emPCR                                                                    emPCR
  **Read length**       400--700 bp[\*](#tfn2-cm-88-278){ref-type="table-fn"}   400 bp                                                                36--151 bp                                        up to 2×150 bp[\*\*](#tfn3-cm-88-278){ref-type="table-fn"}   36--151 bp                 35--75 bp                                                 \> 100 bp[\*\*\*\*\*](#tfn6-cm-88-278){ref-type="table-fn"}              up to 200 bp
  **Type of read**      SE, PE                                                  SE, PE                                                                SE, PE                                            SE, PE                                                       SE, PE                     SE, PE                                                    SE, PE                                                                   SE, PE
  **Output Gb/run**     0.45 -- 0.7                                             0.35                                                                  ≤ 95                                              up to 600[\*\*\*](#tfn4-cm-88-278){ref-type="table-fn"}      \> 1                       77--155[\*\*\*\*](#tfn5-cm-88-278){ref-type="table-fn"}   \> 1[\*\*\*\*\*](#tfn6-cm-88-278){ref-type="table-fn"}                   up to 10
  **Run time**          up to 24 h                                              10 h                                                                  2--14 days                                        27h to 11 days                                               4--27 h                    2--7 days                                                 2 h                                                                      2--4 h
  **Error rate (%)**    1                                                       1                                                                     ≥0.1                                              ≥0.1                                                         \>0.1                      \>0.01                                                    \~1                                                                      
  **Error type**        Indels                                                  Indels                                                                Substitutions                                     Substitutions                                                Substitutions              Substitutions                                             Indels                                                                   
  **Cost of machine**   up to \$ 500k                                           Approx \$115k                                                         approx \$ 540k                                    up to \$740k                                                 approx \$128k              \$525k                                                    approx \$80k                                                             approx \$150k
  **Pros**              Longer reads, faster                                    Good read length, fast                                                Widely used, mature platform                      Ultra high output, ease of use                               Fully automated workflow   Ultra high output, scalable runs; can use 96 bar codes    Cheap, past, label free chemistry, highly scalable                       WGS applications, 384 barcodes supported by the Torrent Suite Software
  **Cons**              High cost per Mb, errors with homo polymer repeats      Like the FLX, plus lowest output among small sequencing instruments   High cost per Mb, low multiplexing capabilities   Less scalability, high overall costs                         Insufficiently used        Shorter read length, long time for clonal preparation     Homopolymer errors, laborious (yet semi-automated) library preparation   Possibly high cost per Mb and errors

SBS = Sequencing by synthesis; SBL = Sequencing by ligation; RDT = Reverse dye terminator; SE = Single-ended read; PE = Paired-ended read

at the lower limit of the range for the Titanium

PE for the 1500 and 2500 on rapid run

for the 2000 and 2500 on high output

155 Gb for the XL model

for the 318 chip

###### 

Some commercially available cancer panel kits.

  Company                          Seq panel                                 Genes included                                                                                                                                                                                                                                                                                                             Targeted disease                                                                                                               Preferred seq machine
  -------------------------------- ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ---------------------------
  Ambry Genetics                   BreastNext                                ATM, BARD1, BRIP1, CDH1, CHEK2, MRE11A, MUTYH, NBN, PALB2, PTEN, RAD50, RAD51C, STK11, TP53                                                                                                                                                                                                                                Mainly hereditary breast and/or ovarian cancer; some genes associated with other cancers                                       Any NGS platform
  Ambry Genetics                   OvaNext                                   *ATM, BARD1, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2,SH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C, STK11, TP53*                                                                                                                                                                                                 Hereditary gynecological cancers (breast, ovarian, uterus)                                                                     Any NGS platform
  Ambry Genetics                   CancerNext                                *APC,ATM, BARD1, BRIP1, BMPR1A, CDH1, CHEK2, EPCAM, MLH, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD50, RAD51C,SMAD4, STK11, TP53*                                                                                                                                                                              Breast, colon, ovarian, uterine, other                                                                                         Any NGS platform
  Multiplicom                      BRCA MASTR™ Dx                            BRCA1, BRCA2                                                                                                                                                                                                                                                                                                               Hereditary breast and/or ovarian cancer                                                                                        Any NGS platform
  Roche NimbleGen                  NimbleGen Sequence Capture arrays         User-designed panels, according to the research aim                                                                                                                                                                                                                                                                        Any type of cancer, known to be related to a particular gene/group of genes                                                    Roche 454/GS Junior
  Ion Torrent/ Life Technologies   Ion AmpliSeq Cancer Hotspot Panel         ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL, EZH2, IDH2   It targets the hotspot regions of 50 oncogenes and tumor suppressor genes which have been related to various types of cancer   Ion Torrent PGM
  Ion Torrent/ Life Technologies   Ion AmpliSeq Comprehensive Cancer Panel   409 oncogenes and tumor suppressor genes (including the 50 genes covered by the Cancer Hotspot Panel)                                                                                                                                                                                                                      It targets genes frequently cited in tumorigenesis, as well as tumor suppressors                                               Ion Torrent PGM
  Illumina                         TruSeq Amplicon -- Cancer Panel           ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL               Able to identify somatic mutations in a high number of mutational hotspots in cancer genomes from various samples              Illumina, including MiSeq
  University of Washington         BROCA Cancer Risk Panel                   APC, ATM, ATR, BABAM1, BAP1, BARD1, BMPR1A, BRCC36, BRIP1, CDH1, CDK4, CDKN2A, CHEK1, CHEK2, EPCAM, FAM175A (Abraxas), MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRSS1, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RBBP8, RET, SMAD4, STK11, TP53, TP53BP1, UIMC1, VHL, XRCC2, and XRCC3                         Mainly hereditary breast and/or ovarian cancer; some genes associated with increased risk of other cancers                     Any NGS platform
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